Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-150 · 6 trials · 4 indications
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPID24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).
Pain intensity was evaluated using the 11-point NRS (where 0 signified no pain and 10 signified worst imaginable pain) during the last 24 hours on the NRS each evening. Higher score indicates greater level of pain.
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0 =no pain to 10 =worst possible pain). SPID24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received placebo matched to VX-150 for 2 days. |
| VX-150 - Dose Level 1 | EXPERIMENTAL | Participants received VX-150 1500 milligrams (mg) as first dose, followed by VX-150 750 mg every 12 hours (q12h) for 2 days. |
| VX-150 - Dose Level 2 | EXPERIMENTAL | Participants received VX-150 1000 mg once daily (qd) for 2 days. |
| VX-150 - Dose Level 3 | EXPERIMENTAL | Participants received VX-150 500 mg q12h for 2 days. |
| VX-150 - Dose Level 4 | EXPERIMENTAL | Participants received VX-150 500 mg as first dose, followed by VX-150 250 mg q12h for 2 days. |
| VX-150 - Dose Level 5 | EXPERIMENTAL | Participants received VX-150 250 mg qd for 2 days. |
| VX-150 | EXPERIMENTAL | - |
| Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | ACTIVE_COMPARATOR | - |
| VX-150, placebo | EXPERIMENTAL | Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2 |
| placebo, VX-150 | EXPERIMENTAL | Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2 |
| VX-548 | EXPERIMENTAL | Participants will be randomized to receive a single dose of different dose levels of VX-548 |
| VX-993 | EXPERIMENTAL | Participants will be randomized to receive a single dose of different dose levels of VX-993. |
| Name | Type | Description |
|---|---|---|
| VX-150 | DRUG | Capsules for oral administration. |
| Placebo | DRUG | Capsules for oral administration. |
| HB/APAP | DRUG | Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days. |
| VX-548 | DRUG | Solution or suspension for oral administration. |
| VX-993 | DRUG | Suspension for oral administration. |
Key Inclusion Criteria: Before surgery: * Body mass index (BMI) of 18.0 to 38.0 kilogram per meter square (kg/m\^2) * Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic block) not t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | N/A | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | - | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | - | Flozin |
VX-150 is an investigational small molecule being developed by Vertex Pharmaceuticals for pain-related conditions, including small fiber neuropathy, osteoarthritis, acute pain, and pain generally. It has been studied in Phase 2 clinical trials for osteoarthritis of the knee and acute pain following bunionectomy.
VX-150 is a small molecule being developed for pain. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not described here.
VX-150 is developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker VRTX. Vertex is conducting clinical trials to evaluate the drug's efficacy and safety in pain indications.
VX-150 is in Phase 2 clinical development. It has completed multiple Phase 2 trials, including studies in osteoarthritis and acute pain, and is not yet approved by regulatory authorities. It remains an investigational drug.
VX-150 has completed several clinical trials. NCT02660424 studied it in osteoarthritis of the knee with 124 participants. NCT03206749 and NCT03764072 evaluated it in acute pain after bunionectomy with 243 and 250 participants, respectively. NCT05418712 was a Phase 1 microneurography study in healthy participants.
No alternative names for VX-150 have been reported. It is identified solely by its development code VX-150 in clinical trial registries and by its developer, Vertex Pharmaceuticals.